Drug Detail

Information about Pictilisib

Generic Name
 Pictilisib
IND
 GDC-0941
Brand Name (US)
Manufacturer
 Piramed
Drug Type
 Kinase inhibitor
Delivery
 Oral
Approval Status
 Phase 1
Indications
Overall Strategy
 Oncogenic Signal Path Based
Strategy
 Block KIT Signal Path
Drug Category
 PI3K inhibitor

GDC-0941 is a potent, selective, oral inhibitor of PI3K. GDC-0941 appears to be selective for the p110α subunit of PI3K.
Targeting signals downstream from KIT and PDGFRA is one strategy being investigated for Gleevec-resistant GIST and for many cancers in general. One of the most promising downstream targets appears to be PI3K.
This drug was initially developed by Piramed in the United Kingdom.

Links

 

 The identification of GDC-0941
   

 

 Pharmacokinetics and pharmacodynamic biomarkers for the pan-PI3K inhibitor GDC-0941: Initial Phase I evaluation
   

Trials of this drug

  

 A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
   

  

 A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable
   

Trial results
  First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors
   
  Pharmacokinetics and pharmacodynamic biomarkers for the pan-PI3K inhibitor GDC-0941: Initial Phase I evaluation
   
  ASCO 2010 - A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors.
   
  ASCO 2010 - A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941.
   

Search for this drug/combination in:

ClinicalTrials.gov

ASCO

Pubmed